Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jäger E. Al-Batran SE, et al. Among authors: ehninger g. Cancer. 2007 May 1;109(9):1897-904. doi: 10.1002/cncr.22622. Cancer. 2007. PMID: 17377918 Free article. Clinical Trial.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Bornhauser M, et al. Among authors: ehninger g. Blood. 2003 Aug 1;102(3):820-6. doi: 10.1182/blood-2002-11-3567. Epub 2003 Apr 3. Blood. 2003. PMID: 12676781 Free article. Clinical Trial.
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F, Schleyer E, Renner U, Schimming C, Schimmelpfennig C, Bornhäuser M, Illmer T, Trümper L, Ehninger G, Schaich M. Kroschinsky F, et al. Among authors: ehninger g. Cancer Chemother Pharmacol. 2004 Jan;53(1):61-7. doi: 10.1007/s00280-003-0700-2. Epub 2003 Sep 3. Cancer Chemother Pharmacol. 2004. PMID: 12955471 Clinical Trial.
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: ehninger g. Blood. 2004 Feb 15;103(4):1495-8. doi: 10.1182/blood-2003-01-0154. Epub 2003 Oct 23. Blood. 2004. PMID: 14576058 Free article. Clinical Trial.
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
le Coutre P, Kreuzer KA, Pursche S, Bonin Mv, Leopold T, Baskaynak G, Dörken B, Ehninger G, Ottmann O, Jenke A, Bornhäuser M, Schleyer E. le Coutre P, et al. Among authors: ehninger g. Cancer Chemother Pharmacol. 2004 Apr;53(4):313-23. doi: 10.1007/s00280-003-0741-6. Epub 2003 Dec 5. Cancer Chemother Pharmacol. 2004. PMID: 14658008
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehninger G, Schleyer E. Bornhauser M, et al. Among authors: ehninger g. Ann Hematol. 2004 Jun;83(6):401-2. doi: 10.1007/s00277-003-0829-4. Epub 2003 Dec 12. Ann Hematol. 2004. PMID: 14673623
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Bornhäuser M, Pursche S, Bonin M, Freiberg-Richter J, Jenke A, Illmer T, Ehninger G, Schleyer E. Bornhäuser M, et al. Among authors: ehninger g. J Clin Oncol. 2005 Jun 1;23(16):3855-6; author reply 3857-8. doi: 10.1200/JCO.2005.05.246. J Clin Oncol. 2005. PMID: 15923584 No abstract available.
813 results